Table 1.

General clinical and genetic characteristics of PPGL patients from the different screening groups.

	iPPGL	sPPGL	fPPGL	P value
Number of patients	86	85	64
Age at diagnosis (median, years)	54.7 (17.3–82.3)	49.6 (11.0–79.0)	39.0 (11.1–70.2)	iPPGL vs fPPGL <0.001 sPPGL vs fPPGL <0.001 iPPGL vs sPPGL 0.015
Females, n (%)	51 (59.3)	50 (58.8)	34 (53.1)	iPPGL vs fPPGL 0.45 sPPGL vs fPPGL 0.49 iPPGL vs sPPGL 0.95
Hypertension present, n (%)  Persistent, n (%)  Paroxysmal, n (%)  Both, n (%)	54/81 (66.7) 37/81 (45.7) 5/81 (6.2) 12/81 (14.8)	74/80 (92.5) 30/80 (37.5) 5/80 (6.3) 39/80 (48.2)	35/58 (61.4) 25/58 (43.9) 0/58 (0) 10/58 (17.5)	iPPGL vs fPPGL 0.45 sPPGL vs fPPGL <0.001 iPPGL vs sPPGL <0.001
BMI (kg/m2)	23.9 (17.2–41.1)	24.8 (17.4–34.3)	23.4 (16.2–37.8)	iPPGL vs fPPGL 0.74 sPPGL vs fPPGL 0.19 iPPGL vs sPPGL 0.28
Mutations in susceptibility genes, n (%)	12/74 (16.2)	17/79 (21.5)	39/64 (60.9)	iPPGL vs fPPGL <0.001 sPPGL vs fPPGL <0.001 iPPGL vs sPPGL 0.41
SDHA, n (%)  SDHB, n (%)  SDHC, n (%)  SDHD, n (%)  VHL, n (%)  RET, n (%)  NF1, n (%)  MAX, n (%)  HRAS, n (%)  EPAS 1, n (%)	0/74 (0) 2/74 (2.7) 1/74 (1.4) 1/74 (1.4) 2/74 (2.7) 1/74 (1.4) 5/74 (6.8) 0/74 (0) 0/74 (0) 0/74 (0)	0/79 (0) 5/79 (6.3) 0/79 (0) 1/79 (1.3) 3/79 (3.8) 5/79 (6.3) 3/79 (3.8) 0/79 (0) 0/79 (0) 0/79 (0)	0/63 (0) 10/63 (15.9) 0/63 (0) 11/63 (17.5) 6/63 (9.5) 8/64 (12.75) 3/64 (4.7) 1/64 (1.6) 0/64 (0) 1/64 (1.6)
Malignancy at presentation, n (%)	5/84 (6.0)	5/85 (5.9)	26/65 (40.0)	iPPGL vs fPPGL <0.001 sPPGL vs fPPGL <0.001 iPPGL vs sPPGL 1.0
PPGL location  Adrenal, n (%)  Extra-adrenal, n (%)  Multifocal, n (%)	77/84 (91.7) 7/84 (8.3) 0/84 (0)	76/85 (89.4) 7/85 (8.2) 2/85 (2.4)	38/64 (59.4) 17/64 (26.6) 9/64 (14.1)	iPPGL vs fPPGL <0.001 sPPGL vs fPPGL <0.001 iPPGL vs sPPGL 0.57

Data are expressed as mean if not stated otherwise with range in parenthesis or frequencies.

BMI, body mass index.